Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies
Merck KGaA, Halix NV, And Others Combine Expertise
An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.
You may also be interested in...
After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.
Coronavirus Update: Moderna Scales Up Manufacturing, Sosei Looks To Structure-Based Design, Taking Stock Of India’s Lockdown
Moderna details plans on how it will make enough of its coronavirus vaccine, and Sosei is using structure-based design technology to target a SARS-CoV-2 non-strucural protein. Meanwhile, the industry in India faces up to lockdown.
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.